Synovial Sarcoma - Pipeline Review, H1 2020

February 2020 | 359 pages | ID: S34368DC203EN
Global Markets Direct

Abstracts

Synovial Sarcoma - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Pipeline Review, H1 2020, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.

Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 11, 10, 8 and 1 respectively.

Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Synovial Sarcoma - Overview
Synovial Sarcoma - Therapeutics Development
Synovial Sarcoma - Therapeutics Assessment
Synovial Sarcoma - Companies Involved in Therapeutics Development
Synovial Sarcoma - Drug Profiles
Synovial Sarcoma - Dormant Projects
Synovial Sarcoma - Discontinued Products
Synovial Sarcoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Synovial Sarcoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Synovial Sarcoma - Pipeline by Accuronix Therapeutics Inc, H1 2020
Synovial Sarcoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2020
Synovial Sarcoma - Pipeline by Advenchen Laboratories LLC, H1 2020
Synovial Sarcoma - Pipeline by Apollomics Inc, H1 2020
Synovial Sarcoma - Pipeline by Biogenera SpA, H1 2020
Synovial Sarcoma - Dormant Projects, H1 2020
Synovial Sarcoma - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Synovial Sarcoma, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Accuronix Therapeutics Inc
Adaptimmune Therapeutics Plc
Advenchen Laboratories LLC
Apollomics Inc
Biogenera SpA
CoBioRes NV
Cue Biopharma Inc
Eli Lilly and Co
ENB Therapeutics LLC
Epizyme Inc
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Immunocore Ltd
Incyte Corp
Johnson & Johnson
Karyopharm Therapeutics Inc
MediGene AG
Merck & Co Inc
Millennium Pharmaceuticals Inc
OncoTherapy Science Inc
Pfizer Inc
Shanghai GeneChem Co Ltd
Tactical Therapeutics Inc
Takara Bio Inc
Tmunity Therapeutics Inc
United Immunity Co Ltd
Xiangxue Life Sciences
Zenyaku Kogyo Co Ltd